BioSpace News Archive

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma.

Aptose Biosciences Inc. today announced the pricing of an underwritten public offering (the “Public Offering”) of 4,912,280 common shares of the Company (the “Common Shares”) at a public offering price of US $1.71 per share.

SeaStar Medical Holding Corporation announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase 10,840,761 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering.

Seelos Therapeutics, Inc. today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 3,404,256 shares of common stock.

Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to acquire all outstanding shares of the common stock of Rain Oncology Inc.

Astellas Pharma Inc. and Pfizer Inc. announced that on Jan. 26, 2024 the European Medicines Agency validated for review a Type II variation application for PADCEV™ with KEYTRUDA® as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer.

Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, announced that it will release financial results for the second quarter of fiscal year 2024 ended December 31, 2023, before the market open on Friday, February 9, 2024.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Sensient Technologies Corporation will hold its conference call to discuss 2023 fourth quarter and year-end results at 8:30 a.m. CST on Friday, February 9, 2024.